3Rosenfeld WE, Liao S, Kramer LD, et al. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monntherapy and concomitant therapy. Epilepsia, 1997, 38(3) : 324 -333.
4Latour P, Biraber A, Polard E, et al. Drug induced enceph- alopathy in six epileptic patients: topiramate? vatproate? or both? Hum Psychopharmacol, 2004, 19(3) : 193-203.
5Mimrod D, Specchio LM, Britzi M, et al. A comparative study of the effect of carbamazepine and valproiee acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy. Epilepsia, 2005 , 46 ( 7 ) : 1046-1054.
6Steinborn B. Pharmaeokinetic interactions of carbamazepine with some antiepileptic drugs during epilepsy treatment in chldren and adolescents. Rocz Akad Med Bialvmst, 2005, (suppl 1):9-15.
7Gisclon LG, Curtin CR, Kramer LD. The steady-state (ss) pharmacokinetics ( PK ) of phenytoin ( Dilantin ) and topiramate in epileptic patients on monotherapy, and during combination therapy. Epilepsia, 1994, 35 ( Suppl 8 ) : 54-55.
8Luszczki JJ, Czuczwar SJ. Gapaentin syrergistically interacts with topiramate in the mouse maximal electroshock seizure model: an isobolographic analysis. Pharmacological Rep, 2006, 58(16) : 944-954.
9Luszczki JJ. lsobolographic analysis of interaction between drugs with nonparallel does-respose relationship curves: a practical application. Naunyn Schmiedebergs Arch Pbarmacol, 2007, 375(2) : 105-114.
10Doose DR, Brodie MJ, Wilson EA, et al. Topiramate and lamotrigine pharmaeokinetics during repetitive monotherapy and combination in epilepsy patients. Epilepsia, 2003 , 44 ( 7 ) : 917-922.
